SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

A Gartner warning about neocloud providers long-term viability, alongside CoreWeaves debt and bond-market stress, has weighed on NBIS and other AI infrastructure stocks. Traders are divided between viewing the selloff as a sector-wide overreaction and a buying opportunityarguing Nebius is better financed than CoreWeaveand worrying about the sustainability of AI infrastructure spending.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is caught in a neocloud-sector selloff as concerns over CoreWeaves debt and bond yields, alongside Gartners warning about the sustainability of AI infrastructure spending, weigh on the group; hot inflation data is adding pressure. Traders are split between fearing further losses and buying the dip, with some arguing IRENs financing and contracted revenue make it less exposed than CoreWeave.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves sharp rebound follows Nvidia CEO Jensen Huangs reassurance that the company is strengthening and its cost of capital is declining, after debt and bond-market concerns fueled a steep selloff. Traders are buying the dip and anticipating short covering, while skeptics argue that distressed debt signals remain unresolved and the bounce may be temporary.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. It will generate domestically produced bitcoin powered by nuclear, hydro, and solar energy. It operates through the Digital Asset Mining and HPC Leasing segments. The company was founded by Paul B. Prager and Nazar M. Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

A high-volume rebound after a steep selloff has drawn attention, with traders crediting CEO Paul Pragers CNBC defense of TeraWulfs AI/HPC business model and Morgan Stanleys reiterated view that shares are mispriced. The move is being debated as a possible reversal or a temporary bounce amid broader concerns about financing costs and AI data-center stocks.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNows AI Passport launch, with NVIDIA as its first partner, is drawing attention as traders view the agent-governance product as a way to monetize enterprise AI. The rally is also being framed as a rotation into software from chip stocks, though traders disagree on whether the breakout will hold or fade near resistance.

Dell Technologies, Inc. is a technology company, providing customers with a broad and innovative solution portfolio to help customers modernize their information technology (IT) infrastructure, address workforce transformation, and offer critical solutions that keep people and organizations connected. It operates through the following segments: Infrastructure Solutions Group (ISG) and Client Solutions Group (CSG). The ISG segment includes servers, networking, and storage, as well as services and third-party software and peripherals that are closely tied to the sale of ISG hardware. The CSG segment includes designs for commercial and consumer customers of desktops, thin client products, and notebooks. The company was founded by Michael Saul Dell in 1984 and is headquartered in Round Rock, TX.

Dell Technologies Inc - Ordinary Shares - Class C

Dell Technologies Inc

Barclays downgrade of Dell and other enterprise-hardware names, citing limited evidence of an AI-spending inflection and concern that higher component pricesnot stronger unit demandare driving revenue growth, is the main focus behind the selloff. Traders are also weighing broader doubts about debt-funded AI infrastructure amid rate concerns, with some calling the drop an overreaction and buying the dip while others see valuations and AI expectations as too high.

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

RGCs sharp rally has revived speculation that the former meme runner could repeat its past surges, with traders pointing to concentrated insider ownership, a reportedly tight share supply and high borrowing costs as potential squeeze factors. Others call the move a pump-and-dump and cite the companys limited business fundamentals, so the squeeze thesis remains speculative.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

CleanSparks steep selloff and lagging performance despite its Meta-backed data-center deal are driving the discussion, with traders pointing to sector weakness, macro pressure, short interest and concerns about financing and management. Bulls view the AI-infrastructure pivot and contracted revenue as long-term positives, while bears question whether those prospects can offset near-term costs and volatility.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Labs Neutron debut has been pushed to 2027 after manufacturing defects in a carbon-composite tank component, weighing on shares and renewing concerns about repeated schedule slips and delayed growth. Traders are split between viewing the drop as an overreaction to a safety-focused delay and questioning managements execution and the timeline for Neutron.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

A semiconductor-sector selloff, fueled by hotter inflation and concerns about AI spending and valuations, is driving attention to SOXL; its 3x leverage amplifies the swings. Traders are split between buying the sharp pullback as an oversold opportunity and expecting more downside amid fears of an AI-driven correction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$SLS Here is the CEO explaining there are 10,000 AML CR2 Patients Each Year in just the US/Eu5/Japan  
 
-- this Short Manipulated $2B Baby Bio is about to be Worth EVERY NICKEL of $50B to Big Pharma - the Instant Gps Phase 3 Results are Announced: 
• GPs PH3 MOS 34/36 Months / BAT ~ 8 wSerious Toxicity. 
 
85 Days Since the 78th Event / we&#39;d been Seeing an Event Every 22 Days ---  
80th EVENT Has Likely Already Happened, Weeks Ago --- Top Line Phase 3 Results NOW Truly Imminent.

Jay Glenn

David Maibaum

Sweden

Captain

5,500% ROI this quarter

Tony M

Keith Thompson

Anthony Sassin

Hawk1979

Anthony

Plum

ming yu

CMSP

LeftyMD

$SLS SLS, this short rigged $2B Baby Bio is about to Release Phase 3 Registrational Trial results giving Gps the FDA Green Light to a $28B Total Addressable Market. 
Gps will Generate Nearly $5B Per YEAR Just for the 12,500 AML CR2/3 Patients   
12,500 Patients 34/36 Month Median OS  
3 Year Dosing Regime  
Co Estimated $300K Rev Per patient year 1, $120K Year 2, $80K Y3  
80% Patient Uptake Rates --- Just shy of $5B in Revenue  
Then ADD in 40,000 AML CR1 Patients Each Year  
5 year Dosing 
+100,000 AML Patients Currently In Remission right now, who&#39;ll benefit from Gps Immunotherapy, right out of the GATE.

StockTwits Web

SELLAS Life Sciences Group Inc

$SLS Do the Math: Load As many as you can. 
Your future self will thank you.  
This short rigged $2.25B Baby Bio is about to Release Phase 3 Registrational Trial results giving Gps the FDA Green Light to a $28B Total Addressable Market.    
• Gps will Generate Nearly $5B Per YEAR Just for the 12,500 AML CR2/3 Patients      
• 12,500 Patients 34/36 Month Median OS     
• 3 Year Dosing Regime     
• Co Estimated $300K Rev Per patient year 1, $120K Year 2, $80K Y3     
• 80% Patient Uptake Rates --- Just shy of $5B in Revenue     
• Then ADD in 40,000 AML CR1 Patients Each Year     
• 5 year Dosing    
• +100,000 AML Patients Currently In Remission right now, who&#39;ll benefit from Gps Immunotherapy, right out of the GATE.

$SLS - • - After this 10x&#39;s to $100+ it still has a double in it. 
 
This short rigged $2.25B Baby Bio is about to Release Phase 3 Registrational Trial results giving Gps the FDA Green Light to a $28B Total Addressable Market.   
• Gps will Generate Nearly $5B Per YEAR Just for the 12,500 AML CR2/3 Patients     
• 12,500 Patients 34/36 Month Median OS    
• 3 Year Dosing Regime    
• Co Estimated $300K Rev Per patient year 1, $120K Year 2, $80K Y3    
• 80% Patient Uptake Rates --- Just shy of $5B in Revenue    
• Then ADD in 40,000 AML CR1 Patients Each Year    
• 5 year Dosing   
• +100,000 AML Patients Currently In Remission right now, who&#39;ll benefit from Gps Immunotherapy, right out of the GATE.

$SLS $12 is going to be $120 / watch. 
  
- • - This short rigged $2B Baby Bio is about to Release Phase 3 Registrational Trial results giving Gps the FDA Green Light to a $28B Total Addressable Market.   
• Gps will Generate Nearly $5B Per YEAR Just for the 12,500 AML CR2/3 Patients     
• 12,500 Patients 34/36 Month Median OS    
• 3 Year Dosing Regime    
• Co Estimated $300K Rev Per patient year 1, $120K Year 2, $80K Y3    
• 80% Patient Uptake Rates --- Just shy of $5B in Revenue    
• Then ADD in 40,000 AML CR1 Patients Each Year    
• 5 year Dosing   
• +100,000 AML Patients Currently In Remission right now, who&#39;ll benefit from Gps Immunotherapy, right out of the GATE.

$SLS Be holding when Trading is Halted.  
85 Days Since the 78th/ we&#39;d been Seeing an event every 22 Days  
 
- • - This short rigged $2B Baby Bio is about to Release Phase 3 Registrational Trial results giving Gps the FDA Green Light to a $28B Total Addressable Market.   
• Gps will Generate Nearly $5B Per YEAR Just for the 12,500 AML CR2/3 Patients     
• 12,500 Patients 34/36 Month Median OS    
• 3 Year Dosing Regime    
• Co Estimated $300K Rev Per patient year 1, $120K Year 2, $80K Y3    
• 80% Patient Uptake Rates --- Just shy of $5B in Revenue    
• Then ADD in 40,000 AML CR1 Patients Each Year    
• 5 year Dosing   
• +100,000 AML Patients Currently In Remission right now, who&#39;ll benefit from Gps Immunotherapy, right out of the GATE.

$SLS Be holding when the Trading is Halted. 
85 Days Since the 78th/ we&#39;d been Seeing an event every 22 Days 
 
- • - This short rigged $2B Baby Bio is about to Release Phase 3 Registrational Trial results giving Gps the FDA Green Light to a $28B Total Addressable Market.  
• Gps will Generate Nearly $5B Per YEAR Just for the 12,500 AML CR2/3 Patients    
• 12,500 Patients 34/36 Month Median OS   
• 3 Year Dosing Regime   
• Co Estimated $300K Rev Per patient year 1, $120K Year 2, $80K Y3   
• 80% Patient Uptake Rates --- Just shy of $5B in Revenue   
• Then ADD in 40,000 AML CR1 Patients Each Year   
• 5 year Dosing  
• +100,000 AML Patients Currently In Remission right now, who&#39;ll benefit from Gps Immunotherapy, right out of the GATE.

 Here is the CEO explaining there are 10,000 AML CR2 Patients Each Year in just the US/Eu5/Japan  
 
-- this Short Manipulated $2B Baby Bio is about to be Worth EVERY NICKEL of $50B to Big Pharma - the Instant Gps Phase 3 Results are Announced: 
• GPs PH3 MOS 34/36 Months / BAT ~ 8 wSerious Toxicity. 
 
85 Days Since the 78th Event / we'd been Seeing an Event Every 22 Days ---  
80th EVENT Has Likely Already Happened, Weeks Ago --- Top Line Phase 3 Results NOW Truly Imminent.